The category recognizes an individual who has been with FDA for at least 15 years and has made significant contributions to regulatory science at the Agency, either through a single scientific contribution or a body of work.
These contributions must have had a lasting impact on the science supporting FDA’s mission and must have demonstrated a lifetime commitment to public health. Current and retired FDA staff may be nominated. Posthumous nominations are also accepted.
Judy Anne Staffa, MS, RPh, PhD (CDER)
For sustained excellence, vision, innovation and dedication in developing and expanding use of population-based data to address drug safety issues and the opioid crisis.
Carl E. Cerniglia, PhD
For an exemplary career as a microbiologist and research leader advancing FDA’s mission of protecting public health and well-being.
Konstantin Chumakov, PhD
For scientific achievements in the development and characterization of poliovirus vaccines were crucial to advancing the global polio eradication campaign.
Peter P. Fu, PhD
For elucidating the biological effects and mechanisms of action of carcinogens and other toxic constituents of foods, drugs, and cosmetic products regulated by the FDA.
Peter Lowell Goering, PhD
For sustained, outstanding contributions and exemplary leadership in toxicology to improve the safety assessment of FDA-regulated products.
Richard Kotz, MS
For 25 years of dedicated service to FDA's Center for Devices and Radiological Health and the field of statistics as a researcher, reviewer, recruiter, mentor, and leader.
Diane Wysowski, BSN, MPH, PhD
For exemplary lifetime service in applying epidemiology to identify and prevent a variety of medication safety problems to promote the public health.
William T. Allaben, PhD
For establishing an interagency agreement with the National Toxicology Program to conduct toxicological assessments on chemicals regulated by FDA
Bob Rappaport, MD
For lasting contributions to the anesthesia, analgesia, and addiction fields by accelerating the discovery and development of new drugs with improved efficacy and safety.